---- 2009 125 -110 1 20 ----

\*

(2008/10/13 2008/6/23 )

CE ) (PL

MDA HDL-C

. (GSH

. 65-41 (

. (

 $.\mathrm{BF}_3/\mathrm{Methanol}$ 

 $n_6$   $n_3/n_6$   $n_3$ 

/ / 2008 23-22 \*

## The Relationship of Fatty-Acid Composition of Female Serum to the Level of some Biochemical Variables and the Possibility of Myocardial Infarction

## Ameera A. Mahmood

Luma A. Al-Bajjary

Department of Chemistry College of Education Mosul University

## **ABSTRACT**

The present study investigates the relationship between fatty-acid composition (in cholesterol ester and phospholipids), the biochemical parameters (total cholesterol, TC; high density lipoprotein-cholesterol, HDL-C; uric acid, malondialdehyde, MDA and glutathione, GSH), the possibility of myocardial infarction and diabetes mellitus in women aged 41-65 years.

Serum samples were divided into two parts. Lipids were extracted from the first part by organic solvents and their compounds were separated by thin-layer chromatyography. Cholesterol ester and phospholipids were hydrolyzed and the produced fatty acids were re-esterified by BF<sub>3</sub>/methanol. Fatty acid-methyl esters were separated and identified by capillary gas chromatography. It was found that patient groups exhibited a higher level in  $n_6$  fatty acids but a lower level in  $n_3$  fatty acids and in the ratio of  $n_3/n_6$  compared with the control group. The second part of serum was used to estimate the biochemical

parameters. Uric acid, TC and MDA showed an increase in their levels while HDL-C, GSH and the ratio of HDL-C/TC exhibited a decrease in their levels in the patient groups.

It was concluded that the increase in  $n_6$ -fatty acids, TC, MDA (the main product of lipid peroxidation) and uric acid( one of the risk signs of having heart artery disease) as well as the decrease in GSH, HDL-C, HDL-C/TC ratio,  $n_3$ -fatty acids and  $n_3/n_6$  fatty acids ratio reflect a negative signs of mycocardial infarction and diabetes mellitus.

**Key words**: essential fatty acids, myocardial infarction, diabetes mellitus, cholesterol.

	(CHI	O) Coronary Heart Diseases
.(2000,	)	(Blum and Cannon, 1998)
Mygaardial		(Al. Tomor and Mahma ad. 2004)
Myocardial		(AL-Tamer and Mahmood, 2004)
/ <b>x</b>	. 1 . 10 1	(Montgomery et al., 1990) Infarction
	lenko and Grebe	
ox- Lov	w-Density Lipop	
		LDL
		Scavenger Receptors
LDL		(Rosenson, 2004)
		.(Singh et al., 2004)
		,LDL
		.(Al-Tamer and Mahmood, 2006)
ı		
,		
		.(Phillips <i>et al.</i> , 2004)
		.(1 mmps et at., 2004)
		(W. 1.1 / 2000)
		.(Walsh <i>et al.</i> , 2000)

)		
·	. 65-41	(
		·
95	,	
68	60	ı
. 65-41	60	
		5
	37	3
	. 18 -	
	.(Habboush, 1982)	
. MERCK	0.25	
ı	.(AL-Tamer and Mahmoo	od, 2004) 2:20:80
nondestructive reagent	ı	2,7-dichlorofluorescein
S		.(Ma <i>et al.</i> , 1995)
	310	

114

. . . . . .

```
BF<sub>3</sub>/Methanol
                        45
                  .(Morrison and Smith, 1964)
Capillary Gas
                                                                  Chromatography
    (CGC) Capillary Gas Chromatography
    Laboratorium Fredersdorf GmbH
                                                           (MDA) Malondialdehyde
        .(Akande and Akinyinka, 2005)
(AL-Zamely et al., 2001)
                                                     )
5,5'-dithio bis-2-nitrobenzoic acid
                                       (SH group)
                                                                           (DTNB)
                                                                   /Syrbio
Allantoine
                                                          .(Annion and Giese, 1976)
                                                                           (Syrbio)
                                                    .(Robyt and White, 1987)
                                                                       /Bicon
                                                                  .(Wieringa, 2001)
                    (HDL-C)
                    HDL
                     .(Tietz, 1999)
```

```
)
                                                                   .CGC
                                              .(Valsta, 1995; Smedman et al., 1999)
                                            .n3, n6
                                                          2,1
                                                                  (Hu et al., 2001)
                      (Kris-Etherton et al., 2001; Hu et al., 2001)
              desaturation
                                                                 .(Enas et al., 2003)
                                                    .(Sacks, 1994)
                                         (Kris-Etherton et al., 2001)
                      (HDL-C)
```

## (Hu et al., 2001)

.

٠1

	,		:1
المصابات باحتشاء العضلة القلبية	النساء المصابات باحتشاء العضلة القلبية وداء السكر	النساء الطبيعيات	الاحماض الدهنية
0.11	0.12	0.02	10.0
0.11	0.12	0.03	10:0 11:0
0.08	0.09	0.02	12:0
0.0	0.0	0.02	13:0
0.72	1.16	0.74	14:0
0.02	0.02	0.02	15:0
10.06	9.38	10.37	16:0
0.0	0.0	0.0	17:0
0.8	0.95	0.87	18:0
0.03	0.05	0.01	20:0
0.0	0.01	0.02	22:0
0.0	0.0	0.01	23:0
0.0	0.0 11.79	0.01	24:0
11.02	11.//	12.1	المجموع % ادية الاصرة المزدوجة
0.0	0.02	0.0	Cis 14:1n
0.02	0.0	0.0	15:1n5
0.35	0.26	0.72	16:1n7
0.0	0.0	0.0	17:1n7
13.0	12.17	16.68	Cis 18:1n9
0.01	0.02	0.0	Cis 18:1 n7
0.0	0.0	0.03	Cis 18:1n 12
0.04	0.02	0.04	Cis 18:1 n9 trans
0.0	0.01	0.01	Cis 22:1 n9
13.42	12.5	17.48	المجموع (%)
0.0	0.0	0.0	يددة الاواصر المزدوجة 16:2 n4
66.63	65.63	0.0 60.24	cis 18:2n6
0.31	0.25	0.55	Cis 18:3 n3
		2.07	
1.37	1.82		20:3n6
0.02	0.03	0.0	20:2n6
5.55	7.19	5.54	Cis 20:4 n6
0.31	0.38	0.81	Cis 20:5 n3 Cis 22:2
0.0	0.08	0.04	Cis 22:5 n3
0.57	0.08	0.83	Cis 22:6 n3
73.57	74.67	67.85	n6
1.19	1.09	2.23	n3
0.016	0.015	0.033	n3/n6

:2

			.2
			المشبعة
0.07	0.09	0.07	10:0
0.0	0.0	0.0	11:0
0.11	0.1	0.05	12:0
0.0	0.0	0.0	13:0
0.82	1.29	0.31	14:0
0.0	0.01	0.01	15:0
24.15	23.22	23.33	16:0
0.01	0.0	0.02	17:0
12.34	11.13	12.86	18:0
0.02	0.02	0.0	20:0
0.0	0.02	0.0	22:0
0.0	0.0	0.0	23:0
0.03	0.0	0.0	24:0
37.55	35.88	36.65	المجموع %
			حادية الاواصر المزدوجة
0.0	0.01	0.02	14:1 cis n
0.0	0.0	0.0	15:1n5
0.39	0.28	0.49	16:1n7
0.02	0.0	0.0	17:1n7
7.78	9.19	11.85	Cis 18:1n9
0.0	0.01	0.0	Cis 18:1 n7
0.02	0.01	0.0	Cis 18:1n 12
0.04	0.04	0.11	Cis 18:1 n9 trans
0.0	0.01	0.04	Cis 22:1 n9
8.25	9.55	12.51	المجموع (%)
			تعددة الاواصر المزدوجة
0.0	0.0	0.0	16:2 n4
36.46	39.03	28.93	cis 18:2n6
0.18	0.12	0.25	Cis 18:3 n3
3.48	2.96	3.31	20:3n6
0.03	0.01	0.03	20:2n6
8.86	6.45	10.1	Cis 20:4 n6
0.39	0.45	1.0	Cis 20:5 n3
0.01	0.0	0.0	Cis 22:2
0.01 3.65	0.01 4.07	0.05	Cis 22:5 n3 Cis 22:6 n3
49.01	48.45	4.81	n6
4.23	4.65	6.11	n3
0.086	0.096	0.144	n3/n6

```
n3 n6
                                  n3
                                          (Holub, 2002)
                          (EPA) Eicposapentaenioic (DHA) Docosahexaenoic acid
EPA
                                                        (TxA2) Thromboxane A2
     ) AA-TxA2
                                   (AA) Arachidonic acid
                                                                          DHA
                                                                 (
                                                                 cyclo-oxygenase
                                    .TxA2
                                             (AA)
                                                        n3
erythrocyte-
                                                                   .deformability
                             nitric oxide
                                      .(Holub, 2002; Connor, 2000)
   n3
                                 Agosti, 2003
                                          EPA
                                                                         n 6
             (n 6
                                         ) AA
                                                          . (Holub, 2002)
             n 6
                                 .(Benatti et al., 2004; Mete et al., 1999) n3
                                                    n3 / n6
                        2 1
                                        .(AL-Juraisy, 2002; Giacometti et al., 2005)
                                                                          n3/ n6
                 n3 / n6
                                        (Minihane et al., 2002; Von-Schacky, 2000)
```

.(Benatti et al., 2004)

118

•

3

:3

P*				
	(60)	(68)	(95)	
	SD:	± Mean		
0.05	0.779 ±3.960	0.574 ± 3.616	0.319± 2.231	/
0.05	2.401± 0.618	3.556±1.808	8.69±0.263	/
0.05	0.907 ± 8.65	$0.880 \pm 6.490$	568. 0± 5.450	100/
0.05	1.019± 7.277	8.458± 1.029	1.101±8.837	100 /
0.01	16.75± 252.4	21.902± 241.21	4.466± 125.79	100/
0.05	1.593 ± 32.13	$3.04 \pm 33.97$	1.982± 39.21	100 /
0.05	0.0146± 0.134	0.095 ± 0.127	$0.069 \pm 0.312$	/

p<0.001

120

. . . . . .

MDA

```
,LDL-C
                       .(Das et al., 2000)
         (Glycosylation)
                                              .(Ataly and Laaksonen, 2002)
            (Reperfusion of blood flow)
                                  .(Simmi, 2003; Raghuvanshi et al., 2005)
              (
                                                       (glutamyl cysteine synthetase)
                                  .(Powell et al., 2002)
                                                           3
.(Alderman and Aiyer, 2004; Hayden, 2002)
                           .(Reyes and Leary, 2003)
                                                Nephropathy
                                            .( Oguntibeju and Fafunso, 2002)
```

```
3
                                                            :
                                                .(Hu et al., 2001; Enas et al., 2003)
                                                                n3
           (Hydroxy –methylglutaryl-CoA reductase) (HMG-CoA reductase)
                              Statins
                                                  2 1
                                                                  .(Levine, 2003)
           n3
                                                                n3
                                           n6
                                       (
                                                                                )
HMG-CoA
                                                                  AA
                            .n3
                                                                        reductase
                                                                  n6 n3
                                                                           n3/n6
                                                              .(AL-Juraisy, 2002)
               (Suryawanshi et al., 2006)
                     (2 1
                                                            n6 n3
             HDL-C
                                                       :HDL
         n3
    .(Hu et al., 2001; Stark et al., 2000) HDL-C
                                                                       EPA, DHA
                               HDL -C
VLDL
                  HDL
    apo A1
                                                               HDL
                                   HDL
                            .(Pikto-Pictkiewic et al., 2005)
```

:HDL-C/TC

HDL-C LDL-C

HDL-C/TC

(Murray et al., 1999)

.(Gupta and Kapse, 2001)

2000

- Agosti, M.; Pugni, L.; Ramenghi, LA.; Mosca, F., and Marini, A., 2003. Hydrolysed on Plasma Amino Acids Blood Fatty Acids and Insulinaemia. Acta Pediatrica Taylor and Francis. 92, (441): pp.34-38.
- Akande, A.A., and Akinyinka, A.O., 2005. Serum Malondialdehyde Levels During Menstral Cycle. African –J. Bio., 4(11): pp.1997-1299.
- Alderman, M., and Aiyer, K.J.V., 2004. Uric Acid: Role in Cardiovascular Disease and Effects of Losartan. Curr. Med. Res. Opin., 20(3): pp.369-379.
- Al-Juraisy, A.A.M., 2002. Lipid Components and Fatty –Acid Composition of Human Serum of Subjects Consuming Dairy Products and of Human Mother Colostrum and Mature Milk. PH.D. of Mosul Univ., Mosul-Iraq
- Al-Tamer, Y.Y., and Mahmood, A.A., 2004. Lipid Components and Fatty Acid Composition of Iraqi Subjects who Smoke and Consume Dairy Products. Nutr. Metab. Cardeovasc. Dis., 14, pp.94-96.
- AL-Tamer, Y.Y., and Mahmood, A.A., 2006. The Influence of Iraqi Mothers Socioeconomic Status on their Milk-Lipid Content. E.J. Clin. Nutr', 60: pp.1400-1405.
- AL-Zamely, O.; AL Nimer, M.S., and AL-Muslih, R.K., 2001. Detection the Level of Peroxynitrite, and Related With Antioxidant Status in the Serum of Patients With Acute Myocardial Infarction. National J. Chem., .4: pp.625-637.
- Annino, J.S., and Giese, R.W., 1976. Clinical Chemistry. 4<sup>th</sup>.ed., Little Brown Company, Boston.
- Ataly, M., and Laaksonen, D.E., 2002. Diabetes, Oxidative Stress and Physical Exercise. J.Sport Sci. Med., 7: pp.1-14.
- Benatti, P.; Peluso, G.; Nicolai, R., and Calvani, M., 2004. Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties. J. A. Coll. Nutr. 23, 4,: pp.281-302.

- Blum, A., and Cannon, R.O., 1998. Effects of Oestrogens and Selective Oestrogen Receptor Modulators on Serum Llipoproteins and Vascular Function. Lidpidology, 9(6): pp.575-586.
- Champe, P.C. and Harvey, R.A., 1994. Lippincott's Illustrated Reviews: Biochemistry. 2nd. Edn., Awalters Kluwer Company Philadelphia.
- Connor, W.E., 2000. Importance of n-3 Fatty Acids in Health and Disease. A.J. Clin. Nutr., 71, (1): pp.1715-1755.
- Das, S.; Vasisht, S.; Das, S.N., and Srivastava, L.M., 2000. Correlation Between Total Antioxidant Status and Lipids peroxidation in Hyper Cholesterolemia. Current Science, 78(4): pp.486-487.
- Enas, E.A.; Senthilkumar, A.; Chennikkara, H., and Bjurlin, M.A., 2003. Prudent Diet and Preventive Nutrition Form Pediatrics to Geriatrics: Current Knowledge and Practical Recommendation. India Health. J., 55: pp.310-338.
- Giacometti, J.; Milin, Č.; Tata, M.; Čuk, M., and Radośeric-Stašič, B., 2005. Incorporation of Fatty Acids toin Tissue Phospholipids in Mice Fed Diets Rich in n-9 and n-6 Fatty Acids. Croatica Chemica Acta Cacaa 78(3): pp.397-404.
- Gupta, S., and Kapse, A., 2001. Lipid Profile Pattern in Diabetics From Central India. InT. J. Diab. Dev. Countries 21: pp.139-145.
- Habboush, A.E., 1982. Separation Methods in Chemical Analysis, Mosul Univ. Press., Mosul, Iraq.
- Hayden, M.R., and Tyagi, S.C., 2002. Uric Acid: A New Look at an Old Rick Marker for Cardiovascular Disease, Metabolic Syndrome, and Type 2 Diabetes Mellitus the Urate-redox shuttle. Meta. and Nutrition. 1: pp.10-12.
- Holub, B.J., 2002. Clinical Nutrition: 4. Omega-3 Fatty Acids in Cardiovascular Care. J.A.M.C., 5(166): pp.608-613.
- Hu, F.; B., Manson, and Willett, W.C., 2001. Types of Dietary Fat and Risk of Coronary Heart Disease: A critical Review. J.A. Coll. Nutrition, 20, 1: pp.5-19.
- Kris-Etherton, P.; Daniels, S.R.; Eckel, R.H.; Engler, M.; Howard, B.V.; Krauss, R.M.; Lichtenstein, B.H.; Sacks, F.; Jeor, S., and Stampfer, M., 2001. Summary of the Scientific Conference on Dietary Fatty Acids and Cardiovascular Health. Circulation, 103: pp.1034-1039.
- Laurance, D.; Bennette, P., and Brown, M., 1997. Clinical Pharmacology. 5th Edn. Churchill Livingstone, London, pp.878-883.
- Levine, L., 2003. Statins Stimulate Arachidonic Acid Release and Prostaglandin I2 Production in Rat Liver Cells. Lipids in Health and Disease, 2(1): pp.1-9.
- Libby, P.; Ridker, P.M., and Maseri, A., 2002. Inflammation and Atherosclerosis. Circulation, 105: pp.1135-1143.
- Ma, J.; Flosom, A.R.; Shahar, E., and Eckfeldt, J.H., 1995. Plasma Fatty Acid Composition as an Inchicator of Habitual Dietary Fat Intake in Middle-aged Adults, A.J. Clin. Nutr., 62: pp.564-571.
- Mete., N; Islk, B.; Erdinc, L., and CÜrkan, F., 1999. The Effect of Fish Oil on Liver and Plasma MDA and Antioxidant Status of Rats. J. of Medical Sciences. 29: pp.1-6.
- Minihani, A.M.; Leigh-Firbank, E.C.; Leak, D.S.; Wright, J.W.; Murphy, M.C., and Griffin, B.A., 2002. Eicosapentaenoic acid and Docosahexaenoic Acid from Fish Oils: Differential Associations with Lipid Responses. Br. J. Nutr., 87(5): pp.435-445

- Montgomery, R.; Conway, T.W., and Spector, M.D., 1990. Biochemistry: Acase-Oriented Approach. The C.V. Mosby Company Battimore.
- Morrison, W., and Smith, L.M., 1964. Preparation of Fatty Acid Methyl Esters and Dimethylacetals from Lipids with Boron Fluoride –Methanol. J.Lipid Research Vol. 5, pp.600-608.
- Murray, R.K.; Granner, D.K.; Mayes, P.A., and Rodwell, V.W., 1999. Harper Biochemistry. McGraw-Hill Publishing Company, London.
- Oguntibeju, O., and Fafunso, M.A., 2002. Relationship Between Serum Ascorbate, Cholesterol and Total Protein Levels in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). J.Med.Sci., 2(5-6): pp.230-233.
- Phillips, M.; Cataneo, R.N.; Cheema, T., and Greenberg, J., 2004. Increased Breath Biomarkers of Oxidative Stress in Diabetes Mellitus. Clin. Chem. Acta., 344: pp.189-194.
- Pikto-Pietkiewicz, W.; Wolkowska, K., and Pasierski, T., 2005. Treatment of Dysliprdemia in Patients Diabetes Mellitus. Pharmacological Reports. 57: pp.10-19.
- Powell, L.A.; Catherwood, M.A.; McMaster, D., and Trmble, E.R., 2002. Reduced Cysteine Availableility and Expression of â Glutamy L-cysteine Synthetase Leads to A reduction in Glutathione Levels in Mesangial Cell Cultures in High Glucose. Diabetes 51, (2): pp.746-753.
- Raghuvanshi, R.; Chandra, M.; Misra, P.C., and Misra, M.K., 2005. Effect of Vitamins on the Platelet Xanthine Oxidase and Lipid Peroxidation in the Patients of Myocardial infarction. Ind. J. Clin. Bio., 20(1): pp.26-29.
- Reyes, A., and Leary, W.P., 2003. The Increase in Serum Uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension: a hypothesis. J. Hypertension, 21: pp.1775-1777.
- Robyt, F.J., and White, J.B., 1987, Biochemical Techniques, Theory and Practice. Wads worth Inc., Belmont. Monterey California.: pp.92-98.
- Rosenson, R.S., 2004. Statins in a atherosclerosis: Lipid-lowering agentsWithantioxidant capabilities. Atherosclerosis, 173: pp.1-12.
- Sacks, F., 1994. Dietary fats and Coronary heart disease. Overview. J.Cardiovasc. Rick, 1: pp.4-8.
- Simmi, K., 2003. Low Blood Glutathione levels in acute Myocardial infarction. Indian J. Medi. Sci. 57: (8): pp.335-337.
- Singh, R.P.; Sharad, S., and Kapur, S., 2004. Free Radicals and Oxidative Stress in Neurodegenerative Diseases: Relevance of Dietary Antioxidants. J. I.A.C.M., 5, 3: pp.218-225.
- Smedman, A.E.M.; Gustafsson, I.B.; Berglund, L.G.T., and Vessby, B.O.H., 1999. Pentadecanoic acid in serum as a marker of intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am. J. Clin. Nutr. 69(1): pp.22-29.
- Stark, K.D.; Park, E.J.; Maines, V.A., and Holub, B.J., 2000. Effect of a Fish –Oil Concentrate On Serum Lipids in Postmenopausal Women receiving and not receiving hormone Replacement Therapy in a placebo-Controlled, double-blind Trial. Am. J. Clin. Nutr. 72: pp.389-394.

- Suryawanshi, N.P.; Bhutey, A.K.; Nagdeote, N.A.; Jadhav, A.A., and Manoorkar, G.S., 2006. Study of Lipid peroxide and Lipid Profile in Diabetes Mellitus. Ind. J. Clin. Bio., 21(1): pp.126-130.
- Tietz, N.V., 1999. Textbook of clinical chemistry: W.B. Saunders company, Philadelphia, Wieringa G., 2001. The Laboratory investigation of hyperlipidaemias, CAD, Clini. Bioch., 3(3): pp.77-81.
- Valsta, L.M., 1995. Effect of rapeseed oil on serum lipoprotein and plasma fatty acids. Ph. D. Thesis, Univ. of Helsinki, Finland.
- Vasilenko, V., and Grebenev, A., 1987. Internal Diseases. Mir Publishers, Moscow.
- Von-Schacky, C., 2000. n-3 fatty acids and the prevention of coronary atherosclerosis. Am. J. Clin. Nutr., 71(1): pp.224-227.
- Walsh, B.A.; Mullick, A.E.; Banka, C.E., and Rutledge, J.C., 2000. 17β-Estradiol acts Separately on the LDL Particle and Artery Wall to Reduce LDL Accumulation. J. Lipid Research, 41: pp.134-141.
- Wieringa, G., 2001. The Laboratory investigation of hyperlipidaemias. CAD, Clinical Biochemistry, 3(3): pp.77-81.